The success of Sildenafil initially drove a period of growth for major pharmaceutical companies, nevertheless recent developments present a uncertain outlook for shareholders. Off-patent alternatives are eroding https://philiphprj615651.blogginaway.com/41940981/the-blue-pill-and-pharma-a-risky-bet